Gland Pharma's stock fell 6% after the trade and was trading at ₹1,751 on the National Stock Exchange.
The developer said in a regulatory statement that the result helped them record their best-ever quarterly and yearly sales.
Quarter on quarter (QoQ), advances grew by 4.47% in Q4 FY24 from ₹1.79 Lakh Crore as of December 31, 2023.
The addition of this new assembly line to the Manesar unit's existing plant-A has greatly increased Maruti's overall production.
Metal index surged by 2.07%, followed by Realty index at 1.09%. Bank, Financial Services, IT, Healthcare, and Consumer Durables indices also registered gains.
Moving annual turnover (MAT) from April 2023 to March 2024 increased by 6.5%, totaling Rs 1.98 trillion, while domestic market volumes dipped by 1%.
Collaborating closely with Orbicular Pharmaceutical Technologies Private Limited, Gland Pharma is actively engaged in the co-development of several complex injectables, including Eribulin Mesylate Injection.
The NFO is available for subscription from April 08 to April 22. The schemes will reopen for continuous sale and repurchase within five Business Days from the date of allotment.
Full-year sales witnessed a 20% YoY increase, with wholesale volumes reaching 401,303 units (up 25%) and retail sales totaling 431,733 units (up 22%).
The company is raising ₹100 Crore from the issue at a price of ₹1000 each. Investors need to apply for a minimum of 10 NCDs in a lot.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.